

Marksans Pharma shareholders vote 'in favour' of issuance of warrants worth INR 365 cr. to global healthcare investment firm OrbiMed

Mumbai, July 9th, 2021 – Marksans Pharma Ltd (NSE: MARKSANS; BSE: 524404), one of the fastest growing pharmaceutical companies in India, in a regulatory filing has informed the shareholders about the outcome of the Extraordinary General Meeting held today. The shareholders have voted in favour of the Board of Directors approval dated June 15, 2021 to issue 493.24 lakhs convertible warrants at INR 74.00 per warrant totalling to INR 365 cr. to OrbiMed, a global healthcare investment firm with over \$19bn assets under management. OrbiMed has an option to convert the warrants into equity shares and thereafter will own around 10.7% stake in the Company. The shareholders have also ratified the Board's approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mr. Mark Saldanha at the said price of INR 74 per warrant.

Commenting on the event, Mr. Mark Saldanha, Managing Director and CEO of the Company said *"We are excited to welcome OrbiMed as a strategic partner in our journey of becoming a global pharmaceutical company. OrbiMed's investment in our company reinvigorates faith in our unique business model. I am confident that OrbiMed's global network and resources will be the one of the key catalysts for Marksans' next leap forward."*

Commenting on the event, Dr. Sunny Sharma, Senior Managing Director of OrbiMed Asia said *"Marksans has a great management team which has built a differentiated model over the years. We believe that Marksans is well positioned for the next stage of growth through its broad OTC and prescription product portfolio. We are excited to be part of this journey."*

Marksans Pharma has created a unique business model through diverse manufacturing base across world along with front-end presence in key markets such as US and Europe. OrbiMed's rich experience and understanding of the healthcare sector across the world will enable Marksans to accelerate efforts of becoming a fully integrated global pharma company.

About Marksans Pharma Ltd

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

About OrbiMed

OrbiMed is a leading healthcare investment firm, with over \$19 billion in assets under management. OrbiMed invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed's team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya.

Investor Relations Team at Marksans Pharma

Jitendra Sharma, CFO

Marksans Pharma Ltd

Tel: +91 022 40012000

jitendra@marksanspharma.com

Ravi Udeshi/ Rahul Thakur

Christensen Investor Relations

Tel : +91 22 4215 0210

rudeshi@christensenir.com

rthakur@christensenir.com

Registered Office

11th Floor, "GRANDEUR"

Off Veera Desai Extension Road

Oshiwara, Andheri West

Mumbai, Maharashtra, 400 053

Telephone: +91 224001 2000

Fax: +91 224001 2011

CIN: L24110MH1992PLC066364

ISIN: INE750C01026

NSE Code: MARKSANS

BSE CODE: 524404

Website: <http://www.marksanspharma.com>

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Marksans Pharma Ltd. and OrbiMed will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
